Shots:
- Harmony to receive $3.5M up front & development and regulatory milestone along with royalties & will acquire full development and commercialization rights globally, Ex- Greater China
- The acquisition of HBS-102 marks a next-generation therapy after Wakix (pitolisant). Additionally, Harmony plans to build a robust portfolio to treat patients with rare neurological diseases & continue to pursue additional assets
- In a preclinical POC study, HBS-102 (MCHR1 antagonist) showed a reduction in cataplexy events in an orexin knockout mouse model of narcolepsy. Additionally, Harmony plans to start the P-II trial
Click here to read full press release/ article | Ref: PR Newswire | Image: Harmony Biosciences
The post Harmony Acquires ConSynance’s Asset for the Treatment of Narcolepsy and other Rare Neurological Diseases first appeared on PharmaShots.
